Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients

被引:90
作者
Wertheim, HFL [1 ]
Vos, MC [1 ]
Ott, A [1 ]
Voss, A [1 ]
Kluytmans, JAJW [1 ]
Vandenbroucke-Grauls, CMJE [1 ]
Meester, MHM [1 ]
van Keulen, PHJ [1 ]
Verbrugh, HA [1 ]
机构
[1] Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands
关键词
D O I
10.7326/0003-4819-140-6-200403160-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Staphylococcus aureus nasal carriage is a major risk factor for nosocomial S. aureus infection. Studies show that intranasal mupirocin can prevent nosocomial surgical site infections. No data are available on the efficacy of mupirocin in nonsurgical patients. Objective: To assess the efficacy of mupirocin prophylaxis in preventing nosocomial S. aureus infections in nonsurgical patients. Design: Randomized, double-blind, placebo-controlled trial. Setting: 3 tertiary care academic hospitals and 1 nonacademic hospital. Patients: 1602 culture-proven S. aureus carriers hospitalized in nonsurgical departments. Intervention: Therapy with mupirocin 2% nasal ointment (n = 793) or placebo ointment (n = 809), twice daily for 5 days, started 1 to 3 days after admission. Measurements: Nosocomial S. aureus infections according to defined criteria, in-hospital mortality, duration of hospitalization, and time to nosocomial S. aureus infection. Staphylococcus aureus isolates were genotyped to assess whether infection was caused by endogenous strains. Results: The mupirocin and placebo groups did not statistically differ in the rates of nosocomial S. aureus infections (mupirocin, 2.6%; placebo, 2.8%; risk difference, 0.2 percentage point [95% CI, -1.5 to 1.9 percentage points]), mortality (mupirocin, 3.0%; placebo, 2.8%; risk difference, -0.2 percentage point [CI, -1.9 to 1.5 percentage points]), or duration of hospitalization (median for both, 8 days). However, time to nosocomial S. aureus infection was decreased in the mupirocin group from 12 to 25 days (P > 0.2). A total of 77% of S. aureus nosocomial infections were endogenous. Limitations: A few infections in both groups may have been missed because investigators assessed a patient for infection only if microbiology culture results were positive for S. aureus. Conclusion: Routine culture for S. aureus nasal carriage at admission and subsequent mupirocin application does not provide effective prophylaxis against nosocomial S. aureus infections in nonsurgical patients.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 27 条
[1]  
Bending M, 1996, J AM SOC NEPHROL, V7, P2403
[2]   THE INFLUENCE OF CALCIUM MUPIROCIN NASAL OINTMENT ON THE INCIDENCE OF STAPHYLOCOCCUS-AUREUS INFECTIONS IN HEMODIALYSIS-PATIENTS [J].
BOELAERT, JR ;
DESMEDT, RA ;
DEBAERE, YA ;
GODARD, CA ;
MATTHYS, EG ;
SCHURGERS, ML ;
DANEELS, RF ;
GORDTS, BZ ;
VANLANDUYT, HW .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (04) :278-281
[3]  
Boelaert JR, 1996, INFECT CONT HOSP EP, V17, P809
[4]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[5]   The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice [J].
Cookson, BD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :11-18
[6]   Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients [J].
Corbella, X ;
Dominguez, MA ;
Pujol, M ;
Ayats, J ;
Sendra, M ;
Pallares, R ;
Ariza, J ;
Gudiol, F .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (05) :351-357
[7]   A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL-TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF MUPIROCIN CALCIUM OINTMENT FOR ELIMINATING NASAL CARRIAGE OF STAPHYLOCOCCUS-AUREUS AMONG HOSPITAL PERSONNEL [J].
FERNANDEZ, C ;
GASPAR, C ;
TORRELLAS, A ;
VINDEL, A ;
SAEZNIETO, JA ;
CRUZET, F ;
AGUILAR, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (03) :399-408
[8]   Interpretive criteria for testing susceptibility of staphylococci to mupirocin [J].
Finlay, JE ;
Miller, LA ;
Poupard, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1137-1139
[9]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[10]   SURVEILLANCE FOR NOSOCOMIAL INFECTIONS - CAN THE SOURCES OF DATA BE REDUCED [J].
GROSS, PA ;
BEAUGARD, A ;
VANANTWERPEN, C .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1980, 1 (04) :233-238